GLP-1 medicines work, they are now cheap in India, and they are prescription drugs for a medical condition. If your doctor puts you on one, how you train decides whether you lose mostly fat or a costly share of muscle.
I am a coach, not a doctor. This post explains what the published research says. It is not medical advice, and nothing here is a reason to start, stop or change a medicine. That decision sits with your endocrinologist or physician. My lane is what happens in the gym and in your week once that decision is made.
Every clinical claim below links to its source. Most are PubMed-indexed papers. Prices and regulation come from news reports and are marked as such.
Why GLP-1 drugs were developed
GLP-1 drugs were built to treat type 2 diabetes. Weight loss was noticed along the way and then pursued deliberately.
GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after a meal. It tells the pancreas to release insulin when blood sugar is high, slows stomach emptying, and signals fullness to the brain. Natural GLP-1 is broken down within minutes, so it could not be used as a medicine as it was (1).
The breakthrough came from an unlikely place. In 1992, researchers isolated exendin-4 from the venom of the Gila monster lizard, a peptide that activates the same receptor but lasts far longer (2). Its synthetic form, exenatide, was approved in the US in 2005 as the first drug in the class. Longer-acting versions followed: liraglutide (daily), then semaglutide (weekly), then tirzepatide, which acts on both the GLP-1 and GIP receptors (3).
People in the diabetes trials lost weight, so higher doses were tested for obesity itself. US approval for weight management came for liraglutide in 2014, semaglutide in 2021 and tirzepatide in 2023 (25).
The mechanism matters for training. These drugs do not burn fat. They make you eat less. In one controlled study, people on semaglutide 2.4 mg ate about 35% less energy at an open buffet meal than people on placebo (4). A GLP-1 is, in practice, a very effective and very aggressive calorie deficit.
The Indian picture
India has the disease burden these drugs were built for, a body type that makes muscle loss more costly, and, since March 2026, some of the lowest prices in the world.
The burden. The national ICMR-INDIAB survey put diabetes at 11.4% of Indian adults, prediabetes at 15.3%, generalised obesity at 28.6% and abdominal obesity at 39.5% (9).
The body type. Indians develop diabetes and heart disease at lower body weights than Europeans. Researchers describe a South Asian pattern of normal BMI, high body and abdominal fat, and low muscle mass (12). This is why Indian guidelines use lower cut-offs. The 2025 revised definition sets Stage 1 obesity at a BMI above 23, and Stage 2 when that comes with a large waist plus functional limits or related disease (10, 11).
The muscle baseline. A Chandigarh study of healthy adults found muscle strength and mass lower than in Caucasian reference groups (13). A study of middle-aged adults in Western India found sarcopenia in 10%, with inadequate protein intake as an independent risk factor (14). Hold on to this point. It is the centre of the training argument later.
The market. These figures come from news reports, not journals, and prices move fast.
- Tirzepatide (Mounjaro) launched in India in March 2025 at roughly ₹14,000 to ₹17,500 a month (report).
- Semaglutide for obesity (Wegovy) followed in June 2025. By October 2025 Mounjaro was India's top-selling drug by value (report).
- The semaglutide patent expired in India on 20 March 2026. Indian generics launched at once, some from about ₹1,290 a month and many between ₹2,200 and ₹4,500 (report).
- The regulator responded the same month. It banned indirect advertising, inspected sellers, and restated that these drugs are to be prescribed by endocrinologists and internal medicine specialists, and by cardiologists for some uses (report).
Indian results so far. Local data is thin. One real-world Indian study of 150 people reported average weight loss of 8.6% on tirzepatide and 5.6% on semaglutide, with 41% reaching a 10% loss (15). That is well below the headline trial numbers. An Indian phase III trial comparing a generic semaglutide with the original has also been published (16). The large trials below were run mostly in non-Indian populations, so treat their numbers as a guide, not a promise.
Who these drugs are for
GLP-1 medicines are for people with type 2 diabetes or clinically diagnosed obesity, usually with related health problems. They are not for dropping five kilos before a wedding.
The main obesity trials enrolled adults with a BMI of 30 or more, or 27 or more with at least one weight-related condition (5). Indian specialists work with lower cut-offs because of the body-type evidence above, and Indian endocrine and bariatric societies have published a stage-wise algorithm built on the Asian definition of obesity (17). Where you sit on that algorithm is your doctor's call.
People who should not use them, or need extra caution, according to the semaglutide prescribing information:
- Anyone with a personal or family history of medullary thyroid cancer or MEN 2 syndrome.
- Anyone pregnant or planning a pregnancy.
An international expert panel also advises screening for eating disorders before starting, because strong appetite suppression can make them worse (25).
The group I worry about is the one the regulator is worried about: people at a healthy or slightly high weight buying generics without a specialist. They get the side effects and the muscle loss without the medical benefit that justifies them.
The pros
In trials, these drugs produce 15% to 21% average weight loss over about 16 months, and semaglutide has been shown to cut heart attacks and strokes in people with existing heart disease.
| Trial | Drug and weekly dose | Length | Average weight change | Placebo |
|---|---|---|---|---|
| STEP 1 (5) | Semaglutide 2.4 mg | 68 weeks | −14.9% | −2.4% |
| SURMOUNT-1 (6) | Tirzepatide 5 mg | 72 weeks | −15.0% | −3.1% |
| SURMOUNT-1 | Tirzepatide 10 mg | 72 weeks | −19.5% | −3.1% |
| SURMOUNT-1 | Tirzepatide 15 mg | 72 weeks | −20.9% | −3.1% |
Every participant in these trials also received lifestyle support. The drug was never tested as a replacement for it.
- Head to head. In a direct comparison of 751 adults, tirzepatide produced 20.2% weight loss against 13.7% for semaglutide at 72 weeks (7).
- Heart protection. In 17,604 adults with existing cardiovascular disease and a BMI of 27 or more, but no diabetes, semaglutide cut the combined rate of cardiovascular death, heart attack and stroke from 8.0% to 6.5% over about 40 months (8).
- Quieter appetite. Many people find it easier to change how they eat once hunger and cravings drop, and the expert consensus treats this as a window for building habits (25).
- Price. For Indian patients who need the drug, generics have removed most of the cost barrier.
The cons
The four real costs are stomach side effects, loss of lean mass, weight regain when the drug stops, and the fact that most people do stop.
Side effects. Nausea and diarrhoea were the most common problems in STEP 1, and 4.5% of people on semaglutide quit because of gut symptoms, against 0.8% on placebo (5). Symptoms are dose-related and usually worst while the dose is being stepped up (25). Rare but serious events exist too. A study of people using semaglutide or liraglutide for weight loss found higher rates of pancreatitis, bowel obstruction and gastroparesis than with another weight-loss drug (18). The absolute numbers were small and the estimates imprecise, but they are the reason these drugs need a doctor.
Lean mass. When you lose weight, you lose some muscle with the fat. A 2026 meta-analysis of 20 trials found lean mass made up about 35% of the weight lost on semaglutide and about 25% on tirzepatide (19). In the tirzepatide body-scan study, people lost 33.9% of their fat mass and 10.9% of their lean mass (20).
Two honest caveats. First, that meta-analysis found diet-only weight loss costs a similar share of lean mass, about 26%. The drug is not uniquely muscle-wasting. It simply produces a much bigger loss, so the absolute amount of lean tissue lost is bigger. Second, scientists disagree on how much this matters. One review argues the changes look adaptive, since a lighter body needs less muscle to move (21). Others argue muscle is too important to metabolic health and ageing to lose casually (22).
Regain. A year after stopping semaglutide, trial participants had regained two-thirds of the weight they lost, and their blood pressure and blood sugar improvements had drifted back (23). People switched from tirzepatide to placebo regained 14% of body weight in a year, while those who stayed on lost a further 5.5% (24).
Most people stop. Large real-world cohorts in the US and Denmark show half or more of users quitting within a year, mostly over cost and access (25). Real-world weight loss is also far lower than in trials. This is the scenario to plan for: a year on the drug, less muscle than you started with, then the weight returning, mostly as fat.
Where GLP-1s fit in the fitness landscape
GLP-1s do not replace training. They change what training is for.
For years the gym was sold as a way to burn calories. The drug now handles the calorie side better than any exercise plan can. What it cannot do is build or keep muscle, strength, bone or fitness. Those remain the job of training, and they are the things that decide how you look, move and age at your new weight.
The best evidence for this comes from a Danish trial of 195 adults with obesity. After an initial diet, they were assigned for a year to exercise, liraglutide, both, or placebo. Against placebo, the exercise group kept off 4.1 kg more, the drug group 6.8 kg, and the combination group 9.5 kg. The combination group also cut body-fat percentage by 3.9 points, about twice as much as either treatment alone (27).
The follow-up is the part I find most useful. In the year after all treatment stopped, people who had only taken the drug regained 6 kg more than people who had done supervised exercise (28). The habit outlasted the prescription.
So the drug and the gym are doing different jobs. The drug decides how much weight you lose. Training decides what that weight is made of, and how much of the result you keep.
Why your training plan has to be built around the drug
A standard fat-loss plan assumes you are hungry, eating enough protein and recovering normally. On a GLP-1 none of those is safe to assume, so the plan has to change.
Why this matters more for Indians. This is my reasoning from the evidence above, not a tested finding. If Indian adults tend to start with less muscle and more fat at the same BMI, and many eat too little protein, then losing a quarter to a third of a large weight loss as lean mass costs us more than it costs the average trial participant.
What the evidence supports. A review in Diabetes Care notes that incretin drugs cost roughly 6 kg of lean mass on average, while supervised resistance training for more than 10 weeks adds about 3 kg of lean mass and 25% more strength. The authors propose resistance training as a standard add-on to these drugs (26). The meta-analysis quoted earlier found that weight loss with resistance training cost only 17.5% lean mass, against 26% without it (19).
One limit to state plainly: no large randomised trial has yet tested resistance training in people taking semaglutide or tirzepatide. The first ones are under way (29). Today's advice is borrowed from diet and surgery research. It is strong, but it is indirect.
The plan
These are the principles I build a GLP-1 client's programme on. The training numbers come from the international expert consensus (25).
- Lift two to three times a week, and make it the priority. Full-body sessions built on squats, hinges, pushes, pulls and carries, at moderate to high effort. If you can only keep one type of exercise, keep this one.
- Train for strength, not for calorie burn. The drug already creates the deficit. Long, exhausting circuits on low food intake add fatigue and little else. Fewer sets, done well, with weights that progress.
- Track performance, not only the scale. If your weight is falling and your lifts are holding or rising, you are losing the right tissue. If your strength is dropping week after week, tell your doctor. The consensus flags losing more than 1.5 kg a week as too fast.
- Walk daily. The consensus target is 150 minutes of moderate activity a week, with 4,000 to 6,000 steps a day as the floor for those who cannot manage that yet.
- Eat protein on purpose. Low appetite makes under-eating protein easy. The consensus suggests 1.2 to 1.5 g per kg of body weight a day during weight loss, and notes that protein alone does not preserve muscle without resistance training. I am not a dietitian. Get your own number from your doctor or a registered dietitian, especially if you have kidney disease.
- Drink more than 2 litres a day. More if you train hard, or through an Indian summer.
Adjust by phase
| Phase | What is happening | How training changes |
|---|---|---|
| Before starting | No drug yet | Learn the main lifts and record baseline strength. A trained body starts with more to keep. |
| Dose step-up | Nausea and low energy are most likely | Shorter sessions, same weights, fewer sets. Train on your better days of the week. Do not train hard on an empty, queasy stomach. |
| Steady weight loss | Appetite low, weight falling fast | Hold or build strength. Keep protein and fluids deliberate. Watch for strength loss. |
| Maintenance | Weight stable on the drug | Push for progress: add load, add muscle. |
| Coming off | Appetite returns | Keep every training habit in place. This is when the exercise habit protects the result. |
If you take diabetes medicines alongside a GLP-1, ask your doctor how to exercise safely around low blood sugar before changing your training.
The bottom line
A GLP-1 is a serious medicine for a serious condition, and for the right person under the right doctor the evidence for it is strong. It is not a shortcut, and it does not do the gym's job. If you and your doctor decide it is right for you, start lifting before the first dose and keep lifting after the last one.
If you are on a GLP-1, or about to start, and want a training plan built around it, message me at @rdj.fitnesslab.
References
- Drucker DJ, Habener JF, Holst JJ. Discovery, characterization, and clinical development of the glucagon-like peptides. J Clin Invest. 2017;127(12):4217-4227. PMID 29202475
- Eng J, et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. J Biol Chem. 1992;267(11):7402-5. PMID 1313797
- Drucker DJ. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. Diabetes Care. 2024;47(11):1873-1888. PMID 38843460
- Friedrichsen M, et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23(3):754-762. PMID 33269530
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID 33567185
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID 35658024
- Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26-36. PMID 40353578
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PMID 37952131
- Anjana RM, et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023;11(7):474-489. PMID 37301218
- Revised definition of obesity in Asian Indians living in India. Diabetes Metab Syndr. 2025;19(1):102989. PMID 39814628
- Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. 2009. PMID 19582986
- Obesity, abdominal obesity, and adipose tissue depots in South Asians with specific reference to Asian Indians: Implications of New Obesity Guidelines. PMID 41293937
- Diagnostic cut-offs, prevalence, and biochemical predictors of sarcopenia in healthy Indian adults: the Sarco-CUBES study. PMID 32504420
- Prevalence and factors associated with sarcopenia among urban and rural Indian adults in middle age: a cross-sectional study from Western India. PMC11444403
- Magnitude and Determinants of Weight Loss Response to GLP-1/GIP Receptor Agonists in India: A Real-World Time-to-Event Analysis. PMC13229245
- Efficacy and safety of semaglutide injection in comparison with reference semaglutide for chronic weight management in Indian adults with obesity: a phase III randomized non-inferiority trial. PMC13054606
- Treatment Algorithm for Patients with Obesity in India: A Joint Consensus by Endocrine Society of India and Obesity Surgeons Society of India. PMID 41979774
- Sodhi M, et al. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA. 2023;330(18):1795-1797. PMID 37796527
- Eisa N, Barood O. Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Diabetes Obes Metab. 2026;28(6):4818-4827. PMID 41877354
- Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729. PMID 39996356
- Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab. 2024;26 Suppl 4:16-27. PMID 38937282
- Prado CM, et al. Muscle matters: the effects of medically induced weight loss on skeletal muscle. Lancet Diabetes Endocrinol. 2024;12(11):785-787. PMID 39265590
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. PMID 35441470
- Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. PMID 38078870
- Sievenpiper JL, et al. Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1-based therapies: an expert consensus statement using a modified Delphi approach. Obes Pillars. 2025;17:100228. PMID 41502845
- Locatelli JC, et al. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? Diabetes Care. 2024;47(10):1718-1730. PMID 38687506
- Lundgren JR, et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. N Engl J Med. 2021;384(18):1719-1730. PMID 33951361
- Jensen SBK, et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment. EClinicalMedicine. 2024;69:102475. PMID 38544798
- LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial. PMC13110620
Safety restrictions are from the US prescribing information for semaglutide 2.4 mg (Wegovy). Market and regulatory details are from the news reports referenced in the text.